Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine Regimens as Preoperative Chemotherapy in Stage I/II NSCLC
NCT00191230Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of gemcitabine in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Complete Pathological Response. Started Sep 2001; status: completed.
02
Drugs
gemcitabine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00191230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00191230.